The interesting paper by Fruchart et al. that appears in this issue of Leukemia and Lymphoma provides a timely reminder that we can always learn lessons from the past. While many clinicians are becoming excited by the emergence of positron emission tomography (PET) using the glucose analogue, fiuorine-18-fruorodeoxyglucose (FDG) for staging and therapeutic monitoring of lymphoma 3 and often believe that this is a new approach to evaluation of this disease, there is a long history of nuclear medicine imaging being used for these purposes that predates PET.
展开▼
